How can a respiratory virus be stopped before it spreads throughout the body? In the MucoShield project, Prime Vector Technologies, the NMI Tübingen, and Fraunhofer IGB are developing an intranasal vaccine candidate against human metapneumovirus (HMPV), which causes hundreds of thousands of cases of severe respiratory disease worldwide each year – especially among children, older people, and immunocompromised individuals.

The NanoLYRIC project: nanoparticles as drug carriers - 13/08/2026

Radiation-activated local chemotherapy

Conventional chemotherapy is associated with severe side effects because cytotoxic drugs act on the whole body. Researchers at the Karlsruhe Institute of Technology and the University Medical Centre Göttingen, in collaboration with Aalen University of Applied Sciences, are developing a novel approach in which a chemotherapeutic agent encapsulated in nanoparticles is released locally and selectively only upon targeted irradiation of the tumour.

Researchers are developing biotechnological processes that enable microbes to produce proteins and vitamins for human consumption using basic chemical ingredients, such as carbon dioxide, hydrogen and oxygen – entirely bypassing livestock farming and agriculture. Because these methods also require energy input, they are popularly called “power-to-protein” and “power-to-vitamin” processes.

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.

The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases.

Robots that can learn and adapt require not only data, AI tools, and algorithms but also direct communication with their users. Jens Kober would like to improve this interaction and as the new head of a research team at Fraunhofer IPA, he is focusing in particular on construction robotics.

Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

Certain medicines contain compounds known as PFAS, which are causing increasing environmental harm due to their long-lasting effects. A report by the University of Freiburg, commissioned by the German Environment Agency, shows that many PFAS-based active ingredients used in medicines can be replaced by alternatives. Based on the findings of the report, doctors will in future be able to give preference to prescribing PFAS-free medicines.

Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.

NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

The life science group Sartorius has opened a new center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market. In Freiburg, the company manufactures essential components such as cytokines and growth factors used in these novel therapies. With an investment of more than 140 million euros, Sartorius is reaffirming its strategic focus on this emerging business area.

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab.

Ulm University held an awards ceremony to recognise the outstanding achievements in research and teaching of its early-career researchers. The event, held at the end of April at Villa Eberhardt, focused on researchers who had received seed funding for their own research projects.

Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

A novel biomimetic tissue substitute combines precisely tunable mechanical properties with biological functionality and is now ready for applications in medical technology. The material was developed in the »PolyKARD« project by Fraunhofer IAP and the NMI Natural and Medical Sciences Institute. From 20.-24.04, 2026, the material will be presented together with further developments at the Hannover Messe, Fraunhofer joint booth.

How can you charge electric cars without plugging them into the power grid for hours on end? How can industrial robots be “refueled” during operation? And how does wireless energy transfer improve medical technology? These questions have occupied Prof. Nejila Parspour, Director of the Institute of Electrical Energy Conversion (IEW) at the University of Stuttgart, for more than twenty years.